Key terms
About KRMD
KORU Medical Systems, Inc. engages in the design, manufacture, and market of proprietary medical devices. Its product portfolio includes FREEDOM60, FreedomEdge syringe drivers, Precision Flow Rate Tubing, and HIgH-Flo Subcutaneous Safety Needle Sets. The company was founded by Andrew I. Sealfon and Adrian W. Zorgniotti on March 24, 1980 and is headquartered in Mahwah, NJ.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest KRMD news
Mar 14
7:20am ET
Analysts’ Top Healthcare Picks: REPRO-MED Systems (KRMD), Catalyst Pharma (CPRX)
Mar 14
7:18am ET
Buy Rating Affirmed for REPRO-MED Systems on Strong Growth Prospects and Innovative Expansion
Mar 14
1:55am ET
Buy Rating Justified: REPRO-MED Systems’ Strong Growth Prospects and Solid Financial Performance
Mar 13
4:07pm ET
Koru Medical sees FY24 revenue $31.2M-$32.2M, consensus $32.26M
Mar 13
4:06pm ET
Koru Medical reports Q4 adjusted EPS (2c), consensus (4c)
Mar 12
9:02am ET
Analysts Offer Insights on Healthcare Companies: OptimizeRx (OPRX), AnaptysBio (ANAB) and REPRO-MED Systems (KRMD)
Mar 11
4:06pm ET
Koru Medical announces feasibility study for rare disease therapy
Mar 11
8:40am ET
Analysts Offer Insights on Healthcare Companies: Clene (CLNN), REPRO-MED Systems (KRMD) and Bioventus (BVS)
Mar 06
9:45am ET
Craig-Hallum Keeps Their Buy Rating on REPRO-MED Systems (KRMD)
Mar 06
8:56am ET
Lake Street Sticks to Their Buy Rating for REPRO-MED Systems (KRMD)
Mar 06
7:11am ET
Koru Medical executes Phase 3 SCIg clinical supply deal with pharma partner
Mar 06
12:15am ET
Buy Rating Affirmed for KORU Medical Systems Amidst Growth and Market Expansion Prospects
No recent news articles are available for KRMD
No recent press releases are available for KRMD
KRMD Financials
Key terms
Ad Feedback
KRMD Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
KRMD Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range